APHRS 2017 / JHRS 2017 Abstract Submission

Period for Abstract Submission

Abstract submission is closed.

Abstract Submission Process

  • Presentation Style and Language
    All abstracts for General Presentation and Symposium must be written in English.
    Style of Presentation Theme Presentaiton
    General Presentation Japanese
    Symposium 1 Inherited arrhythmia syndromes: from bench to bedside Symposium Outline English
    Symposium 2 Regenerative medicine and arrhythmias Symposium Outline English
    Symposium 3 Ablation strategy of long-standing persistent Afib Symposium Outline English
    Symposium 4 Fighting with 'Refractory Ventricular Arrhythmia' Symposium Outline English
    Symposium 5 Reduction in the radiation exposure in non-pharmacotherapy of cardiac arrhythmias Symposium Outline English
    Symposium 6 Anticoagulation therapy to prevent embolic strokes Symposium Outline English
    Symposium 7 Risk assesment and prevention of sudden cardiac death Symposium Outline English
    Symposium 8 Approach to CRT Non-responders Symposium Outline English
    Symposium 9 Role of new defibrillation devices Symposium Outline English
    Symposium 10 How to use remote monitoring Symposium Outline English
    Symposium 11 Non-pharmacotherapy for cardiac arrhythmias in pediatric patients Symposium Outline English

    Overseas applicants should select "only for author from abroad" button, while you are requested to choose your membership type.

  • Body of the Abstract
    The body of the abstract (excluding title, author name(s) and organizational affiliation(s)) must be up to 250 words in English. It may include one diagram, which should be in GIF or JPEG format and of 300 KB or less in size. The diagram can be in either landscape or portrait orientation and will be reduced to about 75 mm x 45 mm when printed. Please note that even if you submit a color diagram, it will be printed in black and white. In case the abstract includes a diagram, the body of the abstract should be up to 150 words.
  • Registration Number and Password

    Upon your abstract submission, you will automatically be assigned a registration number. With this number and your own password, you will be able to access your "My page" and revise your registered abstracts as many times as you wish, up until the deadline of abstract submission.

    You will be responsible for safekeeping of your password and other confidential information. We strongly urge that you keep a note of your registration number and password, as you will need them to confirm receipt of your abstract and revise your submission. Please note that, for security reasons, if you lose or forget your password or registration number we will be unable to provide them to you under any circumstances.

  • Presentation Language for General Presentation
    Please select your presentation language, among “English”, “Japanese or English” and “Japanese preferred” at the time of registration. Note that all slides and posters must be in English only.
  • Presentation Style for General Presentation
    Please select your presentation style, either “oral or poster” or “poster preferred” at the time of registration.
  • Type of Presentation Language
    The presentation language will, in principle, be as per your indication. The presentation style (oral or poster), however, will be determined by the congress secretariat with regard to the schedule.
  • Publication of Accepted Abstracts
    Accepted abstracts will be published in the proceeding in which abstract title, text, author's name and organizational affiliation will be printed exactly as you registered on the website. We recommend you to carefully read the instructions on this website before filling out required information upon submitting your abstract.

Inherited arrhythmia syndromes: from bench to bedside

Wataru Shimizu (Department of Cardiovascular Medicine, Graduate School of Medicine, Nippon Medical School)

Inherited arrhythmia syndromes account for approximately 10% as a cause of sudden cardiac death (SCD) in Asian countries, which include congenital long QT syndrome (LQTS), Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, short QT syndrome, and early repolarization syndrome. Since SCD in inherited arrhythmia syndromes develop generally in young to middle age, it is of particular importance in health policy to reveal its pathophysiology and to prevent SCD. Over the past two decades, molecular genetic studies have established a link between a number of inherited arrhythmia syndromes and mutations in genes encoding for ion channels or other membrane components. In some inherited arrhythmia syndromes such as congenital LQTS, genotype-phenotype correlation has been fully investigated, and attributable to risk stratification as well as genotype-specific therapy in individuals. Recent advances of molecular genetics includes genome-wide association study (GWAS) using gene array and whole exome and whole genome study using next generation sequencer, which are promising tools for identifying new candidate gene responsible for inherited arrhythmia syndromes. In this symposium, expert physicians and researchers are welcome to present their own experience and provide a comprehensive discussion for the growing cutting-edge of SCD due to inherited arrhythmia syndromes.

Regenerative medicine and arrhythmias

Keiichi Fukuda (Department of Cardiology Keio University School of Medicine)

Ablation strategy of long-standing persistent Afib

Atsushi Takahashi (Cardiovascular Center, Yokosuka Kyosai Hospital)

Pulmonary vein isolation is the cornerstone technique of atrial fibrillation (AF) ablation, particularly for paroxysmal AF. On the other hand, in patients with persistent AF, the success rate of pulmonary vein isolation alone is substantially low. To improve the outcome of ablation in persistent AF, several additional ablation strategies, such as linear ablation or complex fractionated atrial electrogram (CFAE) ablation have been explored. The STAR AF-II trial indicated that additional CFAE or linear ablation following pulmonary vein isolation increases the procedural time and does not improve the ablation outcomes in patients with persistent AF. However, patients with persistent AF lasting less than 1 year were included in this trial. Recently, specific substrate modification strategies targeting rotors or low-voltage areas for persistent AF have produced encouraging early results but need to be verified in further studies. Therefore, ablation of long-standing persistent AF is still challenging.
In this symposium, we discuss the efficacy and limitations of different ablation strategies for long-standing persistent AF.

Fighting with 'Refractory Ventricular Arrhythmia'

Kazutaka Aonuma (Department of Cardiology, Faculty of Medicine, University of Tsukuba)

Ventricular tachycardia (VT) and ventricular fibrillation (VF) either with or without underlying heart disease has been demonstrated to be treatment refractory and demonstrated to have poor prognosis.

The implantable cardioverter-defibrillator (ICD) became to be the standard therapy to prevent sudden cardiac death in those patients; however, those malignant ventricular tachy-arrhythmias has been shown to have still poor prognosis when frequent shocks of ICD were observed.

Several studies have been shown that the ablation of the arrhythmogenic substrate of VT/VF could reduce or prevent the recurrence of ventricular tachycardia/ventricular fibrillation in those patients; however, there are many hidden truth to be elucidated.

More recently, stellate ganglion block, which pain physician and/or anesthesiologists routinely perform for the treatment of painful upper extremity sympathetic dystrophy, has been successfully used to the patients with refractory and intractable ventricular tachy-arrhythmias.

Major reasons to have difficulties to treat are that truth of both the basic and the clinical background of the malignant refractory ventricular tachy-arrhythmia remains unknown. The reasons to be clarified are those the lack of true knowledge of the underlying mechanism of VT/VF, the lack of true understanding of 3D arrhythmogenic substrate to maintain VT/VF, the lack of real evaluation of the ablation sizes, and the lack of the true evaluation of the influences of the autonomic tone, etc.

In this symposium, we are delighted to have mostly updated researches to address those questions adequately from both the clinical and the basic fields.

Reduction in the radiation exposure in non-pharmacotherapy of cardiac arrhythmias

Hiroshi Tada (Department of Cardiovasucular Medicine, Faculty of Medical Sciences, University of Fukui)

Ionizing radiation exposure has deterministic effects (e.g., skin injuries, cataracts, etc.) and a long-term cancer risk. Therefore, all physicians have the responsibility to balance the radiation exposure versus the diagnostic and therapeutic gain of the imaging (‘justification’), and to minimize the hazard of a radiation risk to their patients, other staff members, and themselves (‘optimization’). Cardiac electrophysiologists have an exposure per annum two to three times higher than that of diagnostic radiologists. The radiation doses can range from an equivalent of 1–60 milliSievert (mSv) around a reference dose average of 15 mSv (corresponding to 750 chest X-rays) for a cardiac radiofrequency ablation procedure. The reference dose for a regular pacemaker or implantable cardioverter defibrillator implantation is 4 mSv (range 1.4-17) and 22 mSv (range 2.2-95) for a cardiac resynchronization therapy implantation. Doses on the order of a magnitude of 10-100 mSv correspond to a low (albeit definite, not negligible) additional lifetime risk of fatal and non-fatal cancer from between 1 in 1000 (10 mSv) to 1 in 100 (100 mSv). The system and workflow adaptations, use of shielding measures, and use of advanced, non-fluoroscopic imaging techniques can reduce the radiation exposure.
This symposium focuses on methods and techniques to ‘optimize protection’ for patients and operators during non-pharmacotherapy of cardiac arrhythmias. We hope that this symposium will help all the electrophysiologists to reduce the radiation exposure by more than an order of magnitude.

Anticoagulation therapy to prevent embolic strokes

Takeshi Yamashita (The Cardiovascular Institute)

Numerous progresses have been made in anticoagulation therapy to prevent strokes in recent years and greatly improved our clinical practice particularly in patients with atrial fibrillation (AF). These included (1) AF patient stratification with risk scores, (2) development of innovative tools of direct oral anticoagulants (DOACs), and (3) large-scale clinical trials with warfarin and DOACs. More recently, “real world data” has been rapidly accumulated to extrapolate the efficacy under clinical trials to the effectiveness under real world. The information has much contributed to the wide and rapid prevail of effective anticoagulation therapy for AF patients, hopefully leading to decrease in embolic strokes. On the contrary, physicians are apparently annoyed by this deluge of information. Actually, some of them might be misleading or disappointing and thus cannot be extrapolated to our clinical practice, because of differences in races, patient backgrounds and medical environments. In this symposium, we discuss the gaps between medical information and everyday real clinical practice for stroke prevention in AF patients.

Risk assessment and prevention of sudden cardiac death

Yuji Nakazato (Department of Cardiology, Juntendo University Urayasu Hospital)

Sudden cardiac death (SCD) is a major concern in the public health scene even after the wide-spread use of ICD therapy for the prevention of SCD due to fatal ventricular arrhythmias (VA).
To assess the risk of SCD, left ventricular ejection fraction (EF) is known to be the only powerful predictor of SCD in patients with ischemic or non-ischemic cardiomyopathy. Although other methods of assessing electrical activity of the heart or autonomic nervous activity are used for predicting fatal VA or SCD, most of these examinations have insufficient clinical evidence for the prevention of SCD. More reliable risk stratification beyond EF would be expected. In addition, individual risk assessment is also required for other causes of SCD like hereditary fatal VA syndrome.
The trans-venous ICD therapy is currently established as the main tool for primary and secondary prevention of SCD. Recently, subcutaneous ICD has become available in Japan and the clinical efficacy has also been reported. Needless to say, the efficacy of ICD for preventing SCD is obvious;however, serious mechanical and functional complications or infection problems still remain. In addition, the indication gap for primary prevention between the guidelines and real clinical practice is often observed. Various factors may be related to this gap, but it often causes the underuse of ICD even in appropriately indicated patients.
In this session, we would like to discuss a comprehensive approach for preventing SCD from the risk assessment to the efficacy and limitation of ICD therapy.

Approach to CRT Non-responders

Haruhiko Abe (University of Occupational and Environmental Health, Japan)

CRT has been growing as new non-pharmacological therapy in patients with drug refractory heart failure in the world wide, especially in NYHA Class II-IV patients. Presence of wider QRS duration >150msec. and CLBBB, or absence of AF believed to respond well to CRT. In fact that Class I indications in most countries clinical guidelines include these factors in patients with heart failure. Nevertheless, approximately 30-40% of the CRT patients have been reported as non-responder in real world.

In this symposium, we discuss the following clinical important issues;

  • How should we select the CRT patients and what is the most important factor for prediction of responder before CRT?
  • When and how should we assess the patients as responder or non-responder after CRT?
  • Where should we select pacing area at the implantation in both RV and LV sites?
  • How should we manage in non-responder CRT patients?
  • How should we reset the pacing parameters in non-responder CRT patients?

These issues seem to be very important clinical issues in the current CRT management for clinician. We are very welcome to submit your research or clinical data for management of CRT in this symposium.

Role of new defibrillation devices

Takashi Kurita (The Division of Cardiovascular Center, Department of Internal Medicine, Kindai University)

Several large randomized trials have demonstrated the important role of the implantable cardioverter-defibrillator (ICD) for the improvement in mortality in patients with a high risk of sudden cardiac death, regardless of its purpose (primary or secondary prevention) and of underlying heart disease (ischemic or non-ischemic).
MADIT-RIT demonstrated that strict ICD programming to a high-rate (>200 bpm) or long (60sec) duration-delay is associated with a 75% reduction in a 1st inappropriate therapy, and 50% reduction in all-cause mortality in patients for primary prevention. The results from this trial were exciting. However, the fact that a reduction in the inappropriate shocks can be achieved by rigorous programming to this extent represents an immature discrimination capability of the device itself. The establishment of a further advanced algorithm with both a high sensitivity and specificity is required.
Subcutaneous ICDs (S-ICDs) are revolutionary devices to prevent sudden cardiac death without any requirement of venous access. The inability of bradycardia or anti-tachycardia pacing and a relatively high incidence of inappropriate therapies are unresolved problems.
The efficacy of ICDs in patients with newly diagnosed heart failure is limited. To avoid any sudden cardiac death during an appropriate interval to decide the indication of an ICD, a wearable cardioverter-defibrillator (WCD) should be challenged. Through the experience of a wider usage of WCDs, the role of drug therapy for heart failure or acute coronary intervention to prevent sudden cardiac death can be re-evaluated.
In this symposium, the advanced role of several shock-devices, at the present time and in near future, will be discussed.

How to use remote monitoring

Toshiyuki Ishikawa (Department of Cardiology, Yokohama City University Hospital)

Now, remote monitoring of cardiovascular implantable electronic devices (CIEDs) are widely used. Remote monitoring of devices are useful for emergency. It is reported that prognosis of CEIDs patients are improved by remote monitoring of devices. However, burden of the medical staff may be increased. On the other hand, routine hospital visits of the CIEDs patients may be decreased by remote monitoring. Burden of the medical staff can be decreased by appropriate use of monitoring system. Operation of remote monitoring system can be achieved not only by physicians but also other staffs including nurse and medical engineer. Building suppo rt system of remote monitoring in each hospital may be key issue. Important thing is to clarify purposes of remote monitoring system. And we want to know how to use remote monitoring system. We want to discuss about these issues in this symposium and hope many submissions and contribution for this symposium.

Non-pharmacotherapy for cardiac arrhythmias in pediatric patients

Naokata Sumitomo (Department of Pediatric Cardiology, Saitama Medical School International Medical Center)

Abstract Registration

Registration Period

Please click the “Abstract Registration” button at the bottom of this page to access the Abstract Submission page. The registration starts from February 22nd, 2017 until March 23rd, 2017 April 14th, 2017 noon, JST.

Abstract Categories

If you are applying for a general presentation you will be requested to identify the category of your abstract by entering a category number. Please select from the following list the number that best describes the subject of your abstract.

Basic /Translational Science

1 Ion Channels and Transporters: Molecular Structure, Function, and Regulation
2 Ion Channels and Transporters: Micro Anatomy and Pathology
3 Genomics: Bench
4 Genomics: Translational
5 Cell Physiology, Pharmacology, and Signaling
6 Computer Modeling / Simulation
7 Intact Heart Electrophysiology (includes Pharmacology and Optical Mapping)
8 Whole Animal Electrophysiology and Pharmacology (includes Neurohumoral Modulation)

Allied Professionals

9 Clinical Research
10 Teaching Case Reports

Cardiovascular Implantable Electronic Devices

Bradycardia Devices

11 Device Technology
12 Clinical Trials
13 Others

Tachycardia Devices

14 Device Technology
15 Clinical Trials
16 Others

Diagnostic Devices & Sensors

17 Device Technology
18 Clinical Trials
19 Others

Leads & Electrodes

20 Implantation
21 Extraction / Removal
22 Technology
23 Clinical Trials
24 Others

Monitoring & Outcomes

25 Monitoring & Follow-up
26 Outcomes, Quality Measures & Complications

Catheter/ Surgical Ablation


27 Clinical Trials / Outcomes
28 Experimental Methods
29 Quality Measures & Complications
30 Mapping & Imaging
31 Ablation

Atrial Fibrillation & Atrial Flutter

32 Clinical Trials / Outcomes
33 Mapping & Imaging
34 Experimental Methods
35 Ablation
36 Quality Measures & Complications


37 Physiology-Pharmacology
38 Electrocardiography
39 Clinical Trials/ Outcomes
40 Mapping & Imaging
41 Ablation
42 Experimental Methods
43 Quality Measures & Complications

Clinical Electrophysiology

Sudden Cardiac Death

44 Risk Assessment (SAECG/TWA, HRV, QT interval etc. )
45 Epidemiology / Physiology
46 Prevention / Treatment

Syncope & Bradycardia

47 Mechanism / Diagnosis
48 Prevention / Treatment
49 Clinical Trials


50 Atrial fibrillation / Atrial flutter
52 VT / VF / VPC
53 Others

Inherited Disorder

54 Brugada syndrome, Early repolarization syndrome, and Idiopathic VF
55 LQT syndrome, ARVC, and others

Heart Failure

Cardiac Resynchronization Therapy

56 Indications
57 Device Technology
58 LV Leads

Non-CRT Devices for Heart Failure

59 Autonomic Modulation
60 Other

Heart Failure Management

61 Pharmacology
62 Clinical Trials
63 Monitoring

Pediatric / Adult Congenital Heart Disease

64 Pediatric Cardiology
65 Adult Congenital Heart Disease
66 Translational

Policy, Payment & Practice

67 Reimbursement, Regulation and Health Policy
68 Training and Education


69 Teaching Case Reports

Provocative Cases (Case reports)

70 Atrial fibrillation / Atrial flutter
72 VT / VF / VPC
73 Heart Failure
74 Bradycardia Devices
75 Tachycardia Devices
76 Device Implantation / Extraction
77 Pediatric / Congenital Heart Disease
78 Complications
79 Others

Acceptance Results

  • The final decision to accept or reject the submitted abstracts will rest with the congress presidents, based on the reviews of the judges delegated by the congress presidents.
  • Notification of acceptance results will be sent out in the middle of June to the email address that was provided during the registration process. We will also post the results on our website.
  • Please note that we may not be able to fulfill all requests with regard to venue and/or program.
  • If your symposium proposal is not accepted, the abstract will be forwarded for consideration as a general presentation, only in case you have chosen to.

Young Investigator Award (YIA)

Please indicate whether or not you would like your abstract to be forwarded to the YIA selection process. The final nominees will be selected based on peer-review recommendation. Those finalists will make a presentation for the final selection at the YIA session during the congress. Note that you have ever received the YIA in the past, you are not able to apply for the YIA.


  • To qualify for the YIA, candidates must be primary authors who are aged under 40 as of September 1, 2017.
  • If your abstract is nominated for the YIA, you must submit a paper to the "Journal of Arrhythmia (English)".

Page to access the Abstract Registration page

  • Abstract Registration
  • Abstract Modification


To inquire about your application or acceptance result, please email the Congress Secretariat (E-mail: aphrs2017-abs@congre.co.jp). Please be sure to indicate your registration number in your inquiry.)